Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript contains a situation where management conveys that demand is already in hand, the constraint is on the counterparty's ability to receive/absorb, and that counterparty is already working on that preparation, with business ahead. Let's scan the transcript for such a description. Key candidates: Aimovig launch, Repatha, biosimilars, etc. Aimovig: Murdo says "we've been further energized by the remarkable response from physician and patient communities... over 12,000 healthcare professionals prescribe Aimovig resulting in over 100,000 patients starting Aimovig since launch." That's demand already arriving. But is there a receiving-side constraint? He says "The services that we set up to assist patients in gaining early access to the product have been working to resolve requests from the sizeable pent up demand in the market. As we've addressed the initial bolus of patient demand we expect prescription activity to moderate and normalize over the coming weeks." That suggests the company's own services are handling the demand, not a counterparty constraint. The constraint is on the company's own services? Actually it says "services that we set up" - that's the company's own capacity. So not a far-side constraint. Repatha: Murdo talks about improving access, lowering price to reduce out-of-pocket costs for Medicare patients. He says "we've made strong progress to improve patient access to Repatha... too many of them face significant hurdles due to high copay expenses... we made an important decision to improve the access and affordability... This should substantially lower their out-of-pocket costs and lower the abandonment rate... Although the lower price may impact Repatha sales near term, as plans update we expect to see a positive impact on volume growth." This is about the company's pricing strategy to improve access, not about counterparties' capacity to receive. The constraint is patient affordability, not receiving-side capacity. Also, it's about the company's own action. Biosimilars: They launched KANJINTI and AMGEVITA in Europe. They say "we're excited to have launched... we have eight additional biosimilar programs in development and we expect this business to be an important growth driver." No mention of counterparties' capacity to absorb. What about the pipeline? No.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.